期刊
BRITISH JOURNAL OF PHARMACOLOGY
卷 177, 期 20, 页码 4595-4600出版社
WILEY
DOI: 10.1111/bph.15212
关键词
annexin A1; GPCRs; lipoxins; small molecule agonists; therapeutic innovation
资金
- Juvenile Diabetes Research Foundation United Kingdom
- Science Foundation Ireland [15/US/B3130, 15/IA/3152]
- Horizon 2020 Framework Programme [675111]
- William Harvey Research Foundation
- Wellcome Trust [086867/Z/08/Z]
- Wellcome Trust [086867/Z/08/Z] Funding Source: Wellcome Trust
- Science Foundation Ireland (SFI) [15/US/B3130, 15/IA/3152] Funding Source: Science Foundation Ireland (SFI)
One way to develop innovative approaches for the treatment of chronic diseases is to exploit the biology of the resolution of inflammation. With this terminology, we identify the integrated and complex network of mediators and pathways that ensure a timely and spatially regulated inflammatory response. Pro-resolving mediators act on specific receptors. This provides an opportunity for developing a new arm of pharmacology we have termed resolution pharmacology. Here we present the reasoning behind the need to develop new medicines based on resolution and use a prototype GPCR as an example. Understanding how the formyl peptide receptor type 2 (FPR2) operates in a cell-specific manner can guide the development of agonists as new therapeutics that could be of benefit as a therapy or co-therapy for several diseases that affect our society. FPR2 agonists would be among the first drugs to establish resolution pharmacology as the pharmacological approach for the third decade of the millennium.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据